First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a complex disease with a poor prognosis. Selexipag is a selective prostacyclin receptor agonist with vasodilatory, anti-proliferative, anti-inflammatory, and pro-angiogenic properties. However, no clinical data on its therapeutic use in children with PAH are...

Descripción completa

Detalles Bibliográficos
Autores principales: Geerdink, Lianne M., Bertram, Harald, Hansmann, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467934/
https://www.ncbi.nlm.nih.gov/pubmed/28597771
http://dx.doi.org/10.1177/2045893217703369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467934/
https://www.ncbi.nlm.nih.gov/pubmed/28597771
http://dx.doi.org/10.1177/2045893217703369

Ejemplares similares